HENGRUI PHARMA's Hong Kong-listed shares experienced a significant afternoon surge, climbing more than 15% and reaching an intraday high of HKD 76.75.
The catalyst for the move was the company's announcement of a global strategic collaboration and licensing agreement with Bemis (BMS). The partnership is focused on jointly advancing 13 early-stage projects spanning oncology, hematology, and immunology. The objective of the alliance is to accelerate the development of innovative therapeutics for the benefit of patients worldwide.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments